Immunization

Pharmacists are on the front lines of the outbreak, making them well-positioned to educate and counsel patients with vaccine hesitancy.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses how looming tariffs, vaccine misinformation, and rising drug costs are straining public health pharmacy efforts, while also sparking new opportunities for innovation, collaboration, and community-centered care amid uncertainty.

The American Lung Association is raising awareness about updated pneumococcal vaccine guidelines, emphasizing prevention and patient education for at-risk populations.

New research highlights the long-lasting effectiveness of mRNA COVID-19 vaccines, showing sustained B-cell and antibody responses in health care workers over 3 years.

These results suggest that individuals who are immunocompromised with type 2 diabetes (T2D) may need multiple doses of a pneumococcal conjugate vaccine (PCV) to sustain their protection.

The recommendations are not considered to be final until they are published in the Morbidity and Mortality Weekly Report.

Patients who received a pneumococcal 13-valent conjugate vaccination had slightly lower incidence of severe COVID-19 outcomes, but the directions of these associations were mixed.

The findings suggest a positive impact of RSV vaccination on RSV-associated hospital admission, emphasizing the importance of protection in this population.

In a survey among community pharmacists in South Carolina, many pharmacists were unable to correctly identify proper pneumococcal vaccination guideline, raising concerns.

Monetary incentives to receive a COVID-19 vaccine at a public vaccination event may have inadvertently turned away others from receiving a booster, emphasizing the importance of recognizing spillover in trials addressing vaccine hesitancy.

A significant portion of unvaccinated individuals were open to future vaccination.

The poll also showed that social media and general media coverage influenced about 33% of participants to not get vaccinated.

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

The CDC reports 483 total cases across 20 states as of March 28, 2025.

A phase 1/2 clinical trial will provide crucial data on the vaccine's tolerability and pave the way for future development and potential widespread use.

A district leader at CVS Health emphasizes that patients should get tested, be up to date with immunizations, and staying home and reach out to health care professionals when experiencing symptoms.

Jeff A. Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.

The study aims to address lingering public concerns, but its findings and communication have the potential to impact vaccine confidence and public health efforts.

Patients with chronic hepatitis B (CHB) who received the Hecolin hepatitis E virus (HEV) 3-dose regimen had a somewhat low incidence of local and systemic adverse events.

Reported terminations and limitations on research projects studying vaccine hesitancy and strategies to increase vaccine uptake are poised to greatly impact studies of the phenomenon.

The outbreak has grown to a total of 222 confirmed cases of measles, as well as 2 measles-associated deaths.

Officials urge vaccinations as mobile vaccine drives ramp up to contain the outbreak.

PfSPZ-LARC2 is a genetically engineered malaria vaccine that marks a significant step forward in combating malaria around the world.

Many patients may struggle to understand the complex immunization schedules compiled by the CDC.

The approval makes the vaccine the first of its kind for this indication in the United States.

Invasive meningococcal disease is a severe bacterial infection caused by the bacterium Neisseria meningitidis, often leading to meningitis or sepsis.

Antiviral treatments can accelerate healing and reduce complications.

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.

Engaging with the community, providing transparent information to patients, and using noncoercive methods of encouragement are strategies to reduce COVID-19 vaccine hesitancy.

The study shows benefits when Hecolin (HEV 239; Xiamen Innovax Biotech Co Ltd) is administered in 2 doses, rather than the typical 3-dose regimen.